Research Maatschap Cardiologen Rotterdam Zuid
Quick facts
Marketed products
- Prasugrel based short DAPT
- Prasugrel based standard DAPT · Cardiovascular
Prasugrel is a P2Y12 platelet receptor antagonist that irreversibly inhibits platelet aggregation as part of dual antiplatelet therapy (DAPT).
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: